according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	441603-00018	Date of first issue: 06.01.2016

#### **1. PRODUCT AND COMPANY IDENTIFICATION**

Product name	:	Orbifloxacin / Posaconazole / Mometasone Formulation
Manufacturer or supplier's de	etai	ils
Company	:	MSD
Address	:	Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207
Telephone	:	+1-908-740-4000
Emergency telephone number	:	+1-908-423-6000
E-mail address	:	EHSDATASTEWARD@msd.com
Recommended use of the che	em	ical and restrictions on use
Recommended use Restrictions on use	:	Veterinary product Not applicable

#### 2. HAZARDS IDENTIFICATION

#### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification Serious eye damage/eye irri- tation	:	Category 2B
Long-term (chronic) aquatic hazard	:	Category 2
GHS label elements Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H320 Causes eye irritation. H411 Toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention:

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	441603-00018	Date of first issue: 06.01.2016

P264+P265 Wash hands thoroughly after handling. Do not touch eyes.

P273 Avoid release to the environment.

#### **Response:**

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337 + P317 If eye irritation persists: Get medical help. P391 Collect spillage.

#### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

#### Other hazards which do not result in classification

None known.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture
---------------------	---	---------

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 50 - < 70
Orbifloxacin	113617-63-3	>= 1 - < 3
Posaconazole	171228-49-2	>= 0.1 - < 0.25
Mometasone	83919-23-7	>= 0.1 - < 0.25

#### **4. FIRST AID MEASURES**

General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled :	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.
	Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact :	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
	If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention.
Most important symptoms :	Rinse mouth thoroughly with water. Causes eye irritation.
most important symptoms .	

according to the Globally Harmonized System



Vers 3.1	sion	Revision Date: 30.09.2023	-	DS Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
	delayed Protect	ects, both acute and d ion of first-aiders o physician	:	and use the recor when the potentia	ers should pay attention to self-protection, nmended personal protective equipment I for exposure exists (see section 8). cally and supportively.
5. FI	REFIGI	HTING MEASURES			
	Suitable	e extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (C Dry chemical	
	Unsuita media	able extinguishing	:	None known.	
	Specific fighting		:		pustion products may be a hazard to health.
	Hazard	lous combustion prod-	:	Carbon oxides	
	Specific ods	c extinguishing meth-	:	cumstances and t Use water spray t Remove undama so.	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	Special for firef	l protective equipment ighters	:		e, wear self-contained breathing apparatus. ective equipment.
6. A	CCIDEN	NTAL RELEASE MEAS	SUF	RES	
	tive equ	al precautions, protec- uipment and emer- procedures	:	Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).
	Enviror	nmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil se of contaminated wash water. should be advised if significant spillages
		Is and materials for ment and cleaning up	:	For large spills, pur ment to keep mat be pumped, store Clean up remaining bent. Local or national up posal of this mate employed in the c	t absorbent material. rovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. ng materials from spill with suitable absor- regulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- ations are applicable.

according to the Globally Harmonized System



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	441603-00018	Date of first issue: 06.01.2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Technical measures	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation	If sufficient ventilation is unavailable, use with local eventilation.	exhaust
Advice on safe handling	Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene a practice, based on the results of the workplace expo sessment Keep container tightly closed. Take care to prevent spills, waste and minimize rele	osure as-
Conditions for safe storage	environment. Keep in properly labelled containers.	
Materials to avoid	Keep tightly closed. Store in accordance with the particular national regu Do not store with the following product types: Strong oxidizing agents	lations.

#### 7. HANDLING AND STORAGE

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	TWA (Mist)	5 mg/m3	IN OEL
		STEL (Mist)	10 mg/m3	IN OEL
		TWA (Inhal- able particu- late matter)	5 mg/m3	ACGIH
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m3 (OEB 4)	Internal
	Further inform	ation: Skin		
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal
Posaconazole	171228-49-2	TWA	300 µg/m3 (OEB 2)	Internal

#### Components with workplace control parameters

#### Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted.

according to the Globally Harmonized System



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016		
		If handled ir cabinet, fun tial exists fo handle over	processing systems or containment technologies. In a laboratory, use a properly designed biosafety the hood, or other containment device if the poten- or aerosolization. If this potential does not exist, i lined trays or benchtops.		
Perso	onal protective equip	ment			
Respiratory protection Filter type Hand protection		sure assess ommended	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Combined particulates and organic vapour type		
Ma	aterial	: Chemical-re	esistant gloves		
	emarks protection	: Wear safety If the work e mists or aer Wear a face	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols		
Skin a	and body protection	Additional b being perfor suits) to ave	m or laboratory coat. ody garments should be used based upon the task rmed (e.g., sleevelets, apron, gauntlets, disposable bid exposed skin surfaces. riate degowning techniques to remove potentially ed clothing		
Hygie	ene measures	: If exposure flushing sys place. When using Wash conta The effectiv engineering appropriate industrial hy	to chemical is likely during typical use, provide eye tems and safety showers close to the working do not eat, drink or smoke. minated clothing before re-use. e operation of a facility should include review of controls, proper personal protective equipment, degowning and decontamination procedures, vgiene monitoring, medical surveillance and the nistrative controls.		

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: suspension	
Colour	: white to off-white	
Odour	: odourless	
Odour Threshold	: No data available	
рН	: No data available	
Melting point/freezing point	: No data available	

according to the Globally Harmonized System



## Orbifloxacin / Posaconazole / Mometasone Formulation

Vers 3.1	sion	Revision Date: 30.09.2023		S Number: 603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
	Initial b range	oiling point and boiling	:	No data available	
	Flash p	oint	:	No data available	
	Evapor	ation rate	:	No data available	
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	No data available	
	Relative	e vapour density	:	No data available	
	Relative	e density	:	No data available	
	Density	,	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	No data available	
		n coefficient: n-	:	Not applicable	
	octanol Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	Viscosi Visc	ty :osity, kinematic	:	No data available	
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	mixture is not classified as oxidizing.
	Particle	size	:	Not applicable	


#### 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.

according to the Globally Harmonized System



Vers 3.1	ion	Revision Date: 30.09.2023		S Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
		atible materials ous decomposition s		Oxidizing agents No hazardous de	composition products are known.
11. 1	ΓΟΧΙCΟ	LOGICAL INFORMAT	101	1	
	Informa exposu	tion on likely routes of re	:	Inhalation Skin contact Ingestion Eye contact	
	Acute t	oxicity			
	Not clas	ssified based on availa	ble	information.	
	Produc Acute o	<u>et:</u> ral toxicity	:	LD50(Rat): > 2,00 Remarks: No sign No mortality obser	ificant adverse effects were reported
	Acute d	lermal toxicity	:	LD50(Rat): > 2,00 Remarks: No sign	0 mg/kg ificant adverse effects were reported
	Compo		_		
		mineral oil (petroleum pral toxicity	<b>):</b>	LD50 (Rat): > 5,00	no ma/ka
		·	·		
	Acute ir	nhalation toxicity	:	LC50 (Rat): > 5 m Exposure time: 4 I Test atmosphere: Assessment: The tion toxicity	1
	Acute d	lermal toxicity	:	LD50 (Rabbit): > 2 Assessment: The toxicity	2,000 mg/kg substance or mixture has no acute dermal
	Orbiflo	xacin:			
		bral toxicity	:	LD50 (Rat): > 3,00 Remarks: No mor	00 mg/kg ality observed at this dose.
				LD50 (Mouse): > 2 Remarks: No mor	2,000 mg/kg ality observed at this dose.
				LD50 (Dog): > 600 Symptoms: Vomiti Remarks: No mor	
	Acute ir	nhalation toxicity	:	Remarks: No data	available
	Acute d	lermal toxicity	:	Remarks: No data	available





## **Orbifloxacin / Posaconazole / Mometasone** Formulation

Version 3.1	Revision Date: 30.09.2023		9S Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
	te toxicity (other routes of inistration)	:	LD50 (Rat): > 200 Application Route	
			LD50 (Mouse): 50 Application Route	
			LD50 (Rat): 233 n Application Route	
			LD50 (Mouse): 25 Application Route	
	aconazole: te oral toxicity	:	LD50 (Rat): > 5,00	00 mg/kg
			LD50 (Mouse): > 3	3,000 mg/kg
Acu	te dermal toxicity	:	LD50 (Rat): > 2,00	00 mg/kg
Mor	netasone:			
Acu	te oral toxicity	:	LD50 (Rat): > 2,00	00 mg/kg
			LD50 (Mouse): > 2	2,000 mg/kg
Acu	te inhalation toxicity	:	LC50 (Rat): > 3.3 Exposure time: 4 Test atmosphere: Remarks: No mor	h
			LC50 (Mouse): > 3 Exposure time: 4 Test atmosphere:	h
	te toxicity (other routes of inistration)	:	LD50 (Rat): 300 n Application Route Symptoms: Breath	: Subcutaneous
•	n corrosion/irritation classified based on availa	ble	information.	
Pro	duct:			
Spe Res	cies ult	:	Rabbit Mild skin irritation	
<u>Con</u>	nponents:			
Whi	te mineral oil (petroleum	n):		
Spe Res	cies ult	:	Rabbit No skin irritation	

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

ersion I	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
Orbifl	oxacin:		
Speci	es	: Rabbit	
Metho		: Draize Test	
Resul	t	: No skin irritation	n
Posa	conazole:		
Speci		: Rabbit	
Resul	t	: No skin irritation	n
Mome	etasone:		
Speci		: Rabbit	
Resul	t	: No skin irritation	n
Serio	us eye damage/eye	irritation	
Cause	es eye irritation.		
<u>Produ</u>	<u>uct:</u>		
Speci		: Rabbit	
Resul	t	: Mild eye irritatio	n
<u>Comp</u>	oonents:		
White	mineral oil (petrole	eum):	
Speci		: Rabbit	
Resul	t	: No eye irritation	1
Orbifl	oxacin:		
Speci		: Rabbit	
Metho		: Draize Test	
Resul	t	: Mild eye irritatio	n
Posa	conazole:		
Speci		: Rabbit	
Resul	t	: Mild eye irritatio	on
Mome	etasone:		
Speci		: Rabbit	
Resul	t	: No eye irritatior	1
Respi	iratory or skin sens	itisation	
Skin s	sensitisation		
	easified beend as as	ailable information.	

#### **Respiratory sensitisation**

Not classified based on available information.

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

rsion	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
Produ Test Expos Resul	Type sure routes	: Magnusson : Dermal : Not a skin s	-Kligman-Test ensitizer.
Com	oonents:		
White	e mineral oil (petrole	eum):	
Test <sup>-</sup>	Type sure routes ies	: Buehler Tes : Skin contac : Guinea pig : negative	
Orbif	loxacin:		
Test <sup>-</sup> Expos Speci Resul	sure routes les	: Maximisatio : Dermal : Guinea pig : Not a skin s	
Posa	conazole:		
Test <sup>-</sup> Expos Speci Resu	sure routes ies	: Magnusson : Skin contac : Guinea pig : negative	-Kligman-Test t
Mom	etasone:		
Speci	sure routes les ssment lt	: negative : The results	n Test use skin sensitisation. of a test on guinea pigs showed this substance to skin sensitiser.
	<b>cell mutagenicity</b> lassified based on av	ailable information.	
	ponents:		
White	e mineral oil (petrole	eum):	
	toxicity in vitro	•	n vitro mammalian cell gene mutation test ative
Geno	toxicity in vivo	: Test Type: I cytogenetic Species: M	

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Species: Mouse

Result: negative

according to the Globally Harmonized System



/ersion 8.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
		Remarks: E	Based on data from similar materials
Orbif	loxacin:		
Geno	toxicity in vitro	: Test Type: Result: equ	Bacterial reverse mutation assay (AMES) ivocal
		Test Type: Result: pos	Mouse Lymphoma itive
			Chromosomal aberration n: Human lymphocytes itive
Geno	toxicity in vivo	Species: M	Micronucleus test ouse one marrow
		Application Result: neg	Route: Intraperitoneal injection ative
		Species: Ra Cell type: L	iver cells Route: Oral
	cell mutagenicity - ssment	: Weight of e cell mutage	vidence does not support classification as a germ n.
Posa	conazole:		
Geno	toxicity in vitro	: Test Type: Result: neg	Bacterial reverse mutation assay (AMES) ative
		Test Type: Result: neg	Chromosomal aberration ative
Geno	toxicity in vivo	Species: M Cell type: B	one marrow Route: Intravenous
Mome	etasone:		
-	toxicity in vitro	: Test Type: Result: neg	Bacterial reverse mutation assay (AMES) ative
			Chromosomal aberration n: Chinese hamster lung cells ative
			Chromosomal aberration n: Chinese hamster ovary cells

according to the Globally Harmonized System



Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
		_	
		Result: positi	ve
		Test Type: N Result: nega	louse Lymphoma tive
Genc	otoxicity in vivo	: Test Type: N Species: Mo	licronucleus test
		Application Result: nega	Route: Oral
			hromosomal aberration
		Species: Rat Cell type: Bo Result: nega	ne marrow
		Test Type: u Species: Rat	nscheduled DNA synthesis assay
		Cell type: Liv Result: nega	rer cells
	n cell mutagenicity - ssment	: Weight of ev cell mutagen	idence does not support classification as a germ
7330			
	inconicity		
Carc	<b>inogenicity</b> lassified based on av	ailable information.	
<b>Carc</b> Not c	<b>inogenicity</b> lassified based on av <b>ponents:</b>	ailable information.	
Carc Not c <u>Com</u>	lassified based on av ponents:		
Carc Not c <u>Com</u> White Spec	elassified based on av ponents: e mineral oil (petrole ies	eum): : Rat	
Carc Not c <u>Com</u> White Spec Appli	lassified based on av ponents: e mineral oil (petrole ies cation Route	<b>eum):</b> : Rat : Ingestion	
Carc Not c <u>Com</u> White Spec Appli Expo	lassified based on av ponents: e mineral oil (petrole ies cation Route sure time	eum): : Rat : Ingestion : 24 Months	
Carc Not c <u>Com</u> White Spec Appli	lassified based on av ponents: e mineral oil (petrole ies cation Route sure time	<b>eum):</b> : Rat : Ingestion	
Carc Not c <u>Com</u> White Spec Appli Expo Resu	lassified based on av ponents: e mineral oil (petrole ies cation Route sure time	eum): : Rat : Ingestion : 24 Months	
Carc Not c <u>Com</u> White Spec Appli Expo Resu	lassified based on av ponents: e mineral oil (petrole ies cation Route sure time lt	eum): : Rat : Ingestion : 24 Months	
Carc Not c <u>Com</u> White Spec Appli Expo Resu Orbif Spec Appli	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time It floxacin: ies cation Route sure time	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time ilt floxacin: ies cation Route sure time EL	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be	ody weight
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time ilt floxacin: ies cation Route sure time EL	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years	ody weight
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time ilt floxacin: ies cation Route sure time EL ilt ies	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse	ody weight
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli	e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route sure time EL it ies cation Route sure time EL	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse : Oral : Oral	ody weight
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli Expo	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time It floxacin: ies cation Route sure time EL It ies cation Route sure time sure time	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg bo : negative : Mouse : Oral : 2 Years : 200 mg/kg bo	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route sure time EL lt ies cation Route sure time EL	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse : Oral : Oral	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli Expo NOA Resu	elassified based on av ponents: e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route sure time EL lt ies cation Route sure time EL	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse : Oral : 2 Years : 200 mg/kg be	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli Expo NOA Resu	e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route sure time EL lt ies cation Route sure time EL lt ies cation Route sure time EL lt	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse : Oral : 2 Years : 200 mg/kg be	
Carc Not c Com White Spec Appli Expo Resu Orbif Spec Appli Expo NOA Resu Spec Appli Expo NOA Resu Spec Appli Expo NOA Resu	e mineral oil (petrole ies cation Route sure time lt floxacin: ies cation Route sure time EL lt ies cation Route sure time EL lt ies cation Route sure time EL lt	eum): : Rat : Ingestion : 24 Months : negative : Rat : Oral : 2 Years : 200 mg/kg be : negative : Mouse : Oral : 2 Years : 200 mg/kg be : negative	

according to the Globally Harmonized System



	30.09.2023	SDS Number:Date of last issue: 04.04.2023441603-00018Date of first issue: 06.01.2016
Resul Rema		: positive : The mechanism or mode of action is not relevant in huma
Speci Applio	es cation Route	: Mouse : Oral
	sure time	: 2 Years
Resu		: positive
Rema	arks	: The mechanism or mode of action is not relevant in huma
Mom	etasone:	
Speci	es	: Rat
Applio	cation Route	: Inhalation
	sure time	: 2 Years
Dose		: 0.067 mg/kg body weight
Resu	lt	: negative
Speci	05	: Mouse
	cation Route	: Inhalation
	sure time	: 19 Months
Dose		: 0.160 mg/kg body weight
Resu	lt	: negative
Repr	oductive toxicity	
Not cl	lassified based on ava	
Not cl <u>Com</u> White	assified based on ava	
Not cl Comj White Effect	lassified based on ava <u>conents:</u> e mineral oil (petrole	<ul> <li>Im):</li> <li>Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact</li> </ul>
Not cl Com White Effect	lassified based on ava <u>ponents:</u> e mineral oil (petrole is on fertility	<ul> <li>Im):         <ul> <li>Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative</li> <li>Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion</li> </ul> </li> </ul>
Not cl <u>Comj</u> White Effect ment Orbif	assified based on ava <u>ponents:</u> e mineral oil (petroled is on fertility is on foetal develop-	<ul> <li>Im):         <ul> <li>Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative</li> <li>Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion</li> </ul> </li> </ul>

according to the Globally Harmonized System



Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
		Result: No te	I toxicity: LOAEL: 333 mg/kg body weight ratogenic effects, Embryotoxic effects and ad- on the offspring were detected only at high ma-
		Species: Rab Application R General Toxic Embryo-foeta Result: No eff toxic effects a	oute: Oral city Maternal: NOAEL: 20 mg/kg body weight al toxicity: NOAEL: 60 mg/kg body weight fects on early embryonic development, Embryo- and adverse effects on the offspring were detect- h maternally toxic doses, Reduced maternal
	productive toxicity - As- ssment	: Some eviden animal experi	ce of adverse effects on development, based on iments.
Ро	saconazole:		
Eff	ects on fertility	Species: Rat, General Toxic	city - Parent: NOAEL: 180 mg/kg body weight lo effects on mating performance
		Species: Rat, General Toxic	city - Parent: NOAEL: 45 mg/kg body weight lo effects on mating performance
Eff me	ects on foetal develop- nt	Species: Rat, Application R Development	
		Species: Rab	al Toxicity: LOAEL: 40 mg/kg body weight
	productive toxicity - As- ssment	: Some eviden animal experi	ce of adverse effects on development, based on ments.

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
	<b>etasone:</b> ts on fertility	Fertility: NOAE Symptoms: Re weight	rtility oute: Subcutaneous EL: 0.015 mg/kg body weight educed embryonic survival, Reduced foetal ects on fertility, Effect on reproduction capacity
Effec ment	ts on foetal develop-	Species: Mous Application Ro Embryo-foetal	abryo-foetal development se oute: Subcutaneous toxicity: LOAEL: 0.06 mg/kg body weight otoxic effects., Teratogenicity and developmen-
		Species: Rat Application Ro Embryo-foetal	ibryo-foetal development oute: Dermal toxicity: LOAEL: 0.3 mg/kg body weight o-foetal toxicity
		Species: Rabb Application Ro Embryo-foetal	
		Species: Rat Application Ro	bryo-foetal development oute: Subcutaneous toxicity: LOAEL: 0.15 mg/kg body weight s on newborn
		Species: Rabb Application Ro Embryo-foetal	
Repr sessi	oductive toxicity - As- ment	animal experin	e of adverse effects on development, based on nents., Some evidence of adverse effects on n and fertility, based on animal experiments.

#### STOT - single exposure

Not classified based on available information.

#### **Components:**

#### Mometasone:

Remarks

: Based on available data, the classification criteria are not met.

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:
3.1	30.09.2023

```
SDS Number:Date of last issue: 04.04.2023441603-00018Date of first issue: 06.01.2016
```

#### STOT - repeated exposure

Not classified based on available information.

#### Components:

#### Posaconazole:

Exposure routes Target Organs Assessment	<ul> <li>Ingestion</li> <li>Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system</li> <li>Causes damage to organs through prolonged or repeated</li> </ul>
Mometasone:	exposure.
Exposure routes Target Organs Assessment	<ul> <li>inhalation (dust/mist/fume)</li> <li>Immune system, Liver, Kidney, Skin</li> <li>May cause damage to organs through prolonged or repeated</li> </ul>

# : May cause damage to organs through prolonged or repeated exposure.

#### Repeated dose toxicity

#### **Components:**

#### White mineral oil (petroleum):

white mineral of (petroleum):	
Species	Rat
LOAEL	160 mg/kg
Application Route	Ingestion
Exposure time	90 Days
Species	Rat
LOAEL	>= 1 mg/l
Application Route	inhalation (dust/mist/fume)
Exposure time	4 Weeks
Method	OECD Test Guideline 412
Orbifloxacin: Species NOAEL LOAEL Application Route Exposure time Target Organs	Rat 20 mg/kg 80 mg/kg Oral 3 Months Testis, Liver, Kidney, spleen
Species	Mouse
NOAEL	80 mg/kg
LOAEL	250 mg/kg
Application Route	Oral
Exposure time	3 Months
Species	Juvenile dog
NOAEL	50 mg/kg

according to the Globally Harmonized System



Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
Expo	cation Route sure time et Organs otoms	: 250 mg/kg : Oral : 14 Days : Heart, Bone : Gastrointestii : mortality obs	nal disturbance erved
Expo	EL EL cation Route sure time et Organs	: Juvenile dog : 2 mg/kg : 3 mg/kg : Oral : 90 Days : Bone : No significan	t adverse effects were reported
		: Dog : 37.5 mg/kg : Oral : 30 Days	
	EL EL cation Route sure time	: Cat : 7.5 mg/kg : 22.5 mg/kg : Oral : 1 Months : Gastrointestin	nal disturbance
Speci LOAE Applic Expos		: Rat, female : 5 mg/kg : Oral : 6 Months : Adrenal gland	d, Lungs, Heart, Liver, spleen, Kidney, Ovary
Expo		: Dog : 3 mg/kg : Oral : 392 Days : Lungs, Liver, cord, lympho	Brain, small intestine, Adrenal gland, Spinal id tissue
Expo		: Monkey : 15 mg/kg : Oral : 1 Months : Bone marrow	ν, Adrenal gland, Lymph nodes, Blood
Expo		: Dog : 3 mg/kg : Oral : 56 Weeks : Adrenal gland	d, Bone marrow, Kidney, Nervous system,

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
Expo Targ Spec LOA Appl Expo	EL lication Route osure time let Organs cies	: Monkey : 180 mg/kg : Oral : 12 Months : Blood, Gastroin : Monkey : 8 mg/kg : Intravenous : 1 Months	s gland, Testis, lymphoid tissue ntestinal tract, spleen ar system, Lungs, Adrenal gland, Blood
Spec NOA LOA Appl Expo	NEL	: Rat : 0.005 mg/kg : 0.3 mg/kg : Oral : 30 d : Lymph nodes,	Liver, Adrenal gland, Skin, thymus gland
Expo		: Dog : 0.5 mg/kg : Oral : 30 d : Lymph nodes,	Liver, Adrenal gland, Skin, thymus gland
Expo		: Rat : 0.00013 mg/l : inhalation (dus : 90 d : Adrenal gland, Kidney, Liver, t	Lungs, Lymph nodes, spleen, Bone marrow,
Expo		: Dog : 0.0005 mg/l : inhalation (dus : 90 d : Adrenal gland, Kidney, thymus	Lungs, Lymph nodes, spleen, Bone marrow,

#### Aspiration toxicity

Not classified based on available information.

#### Components:

#### Mometasone:

Not applicable

according to the Globally Harmonized System



# Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	441603-00018	Date of first issue: 06.01.2016

#### Experience with human exposure

Components:		
Orbifloxacin:		
Ingestion	:	Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash Remarks: May cause photosensitisation.
Posaconazole:		
Ingestion	:	Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance
Mometasone:		
Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper res- piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching
Further information		
Components:		
Mometasone:		
Remarks	:	Dermal absorption possible

#### 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

White mineral oil (	petroleum):
---------------------	-------------

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox- icity)	:	NOEC: 1,000 mg/l Exposure time: 28 d Species: Oncorhynchus mykiss (rainbow trout)
Toxicity to daphnia and other	:	NOEC: 1,000 mg/l

according to the Globally Harmonized System



Vers 3.1	ion	Revision Date: 30.09.2023		S Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
	aquatic ic toxici	invertebrates (Chron- ty)		Exposure time: 21 Species: Daphnia	d magna (Water flea)
	Posaco	onazole:			
	Toxicity	<i>t</i> to fish	:	Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
	Toxicity plants	v to algae/aquatic	:	EC50 ( Pseudokir 0.509 mg/l Exposure time: 72 Method: OECD Te	
				NOEC (Pseudoki mg/l Exposure time: 72 Method: OECD Te	
	M-Facto icity)	or (Acute aquatic tox-	:	1	
	Toxicity	to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
	Toxicity icity)	to fish (Chronic tox-	:	NOEC: 0.206 mg/ Exposure time: 33 Species: Pimepha Method: OECD Te	d Iles promelas (fathead minnow)
		v to daphnia and other invertebrates (Chron- ity)	:	Method: OECD Te	d magna (Water flea)
	M-Facto toxicity)	or (Chronic aquatic )	:	1	
	Momet	asone:			
	Toxicity	v to fish	:	Exposure time: 96	ryllina (Silverside)): 0.11 mg/l 5 h city at the limit of solubility
				LC50 (Cyprinodor	n variegatus (sheepshead minnow)): > 5 mg/l

according to the Globally Harmonized System



Version 3.1	Revision Date: 30.09.2023		DS Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
			Exposure time: 7 Remarks: No toxic	d city at the limit of solubility
	kicity to daphnia and other latic invertebrates	:	Exposure time: 48 Method: OECD Te	
To: pla	kicity to algae/aquatic nts	:	mg/l Exposure time: 72 Method: OECD Te	
То	kicity to microorganisms	:	Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
			NOEC: 1,000 mg/ Exposure time: 3 Test Type: Respir Method: OECD Te Remarks: No toxid	h ation inhibition
To: icit <u>y</u>	<pre>kicity to fish (Chronic tox- /)</pre>	:	NOEC: 0.00014 m Exposure time: 32 Species: Pimepha Method: OECD Te	2 d Iles promelas (fathead minnow)
aqı	kicity to daphnia and other uatic invertebrates (Chron- oxicity)	:	Method: OECD Te	magna (Water flea)
	Factor (Chronic aquatic icity)	:	100	
Pe	sistence and degradabil	ity		
<u>Co</u>	mponents:			
	i <b>te mineral oil (petroleun</b> degradability	n): :	Result: Not readily Biodegradation: 3 Exposure time: 28	31 %

according to the Globally Harmonized System



Version 3.1	Revision Date: 30.09.2023		DS Number: 1603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
Posa	conazole:			
Biode	egradability	:	Result: Not read Biodegradation: Exposure time: 2 Method: OECD	50 %
Stabi	lity in water	:		i life (DT50): > 30 d Test Guideline 111
Mom	etasone:			
Biode	egradability	:	Biodegradation: Exposure time: 2	
Stabi	lity in water	:	Hydrolysis: 50 % Method: OECD	o(12 d) Test Guideline 111
Bioa	ccumulative potential			
Com	ponents:			
Posa	conazole:			
Bioad	ccumulation	:	Bioconcentration	is macrochirus (Bluegill sunfish) h factor (BCF): 20 Fest Guideline 305
	ion coefficient: n- nol/water	:	log Pow: 4.15	
Mom	etasone:			
Bioad	ccumulation	:	Bioconcentration	is macrochirus (Bluegill sunfish) n factor (BCF): 107.1 Test Guideline 305
	ion coefficient: n- nol/water	:	log Pow: 4.68	
Mobi	lity in soil			
Com	ponents:			
Posa	conazole:			
	bution among environ- al compartments	:	log Koc: 5.52	
Mom	etasone:			
Distri	bution among environ-	:	log Koc: 4.02	

according to the Globally Harmonized System



## Orbifloxacin / Posaconazole / Mometasone Formulation

	Version 3.1	Revision Date: 30.09.2023	SDS Number: 441603-00018	Date of last issue: 04.04.2023 Date of first issue: 06.01.2016
--	----------------	---------------------------	-----------------------------	---

mental compartments

#### Other adverse effects

No data available

#### **13. DISPOSAL CONSIDERATIONS**

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

#### 14. TRANSPORT INFORMATION

#### International Regulations

<b>UNRTDG</b> UN number Proper shipping name	:	UN 3082 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
Class Packing group Labels Environmentally hazardous	: : :	(Mometasone, Posaconazole) 9 III 9 yes
<b>IATA-DGR</b> UN/ID No. Proper shipping name	:	UN 3082 Environmentally hazardous substance, liquid, n.o.s. (Mometasone, Posaconazole)
Class Packing group Labels Packing instruction (cargo	:	(Mometasone, Posaconazole) 9 III Miscellaneous 964
aircraft) Packing instruction (passen- ger aircraft) Environmentally hazardous	:	964 yes
<b>IMDG-Code</b> UN number Proper shipping name	:	UN 3082 ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
Class Packing group Labels EmS Code Marine pollutant	: : : : : : : : : : : : : : : : : : : :	(Mometasone, Posaconazole) 9 III 9 F-A, S-F yes

according to the Globally Harmonized System



### Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:
3.1	30.09.2023	441603-00018

Date of last issue: 04.04.2023 Date of first issue: 06.01.2016

#### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 15. REGULATORY INFORMATION

#### Safety, health and environmental regulations/legislation specific for the substance or mixture

#### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### **16. OTHER INFORMATION**

Revision Date :		30.09.2023	
Further information			
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/	
Date format	:	dd.mm.yyyy	
Full text of other abbreviation	ns		
ACGIH IN OEL	:	USA. ACGIH Threshold Limit Values (TLV) India. Permissible levels of certain chemical substances in work environment.	
ACGIH / TWA IN OEL / TWA IN OEL / STEL	:	8-hour, time-weighted average Time-Weighted Average Concentration (TWA) (8 hrs.) Short-term exposure Limit STEL (15 min)	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

#### SAFETY DATA SHEET according to the Globally Harmonized System



## Orbifloxacin / Posaconazole / Mometasone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	441603-00018	Date of first issue: 06.01.2016

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN